Catalyst
Recent Long Lower Shadow signals on March 6 and March 23 indicate bullish bias for RARE.
Purple Biotech announced an AI collaboration with Converge Bio to accelerate its next-generation Tri-Specific Antibody Platform.
Risk
MACD Death Cross signals on February 13 and March 18 indicate biased bearish momentum for RARE.
Analyst consensus is mixed with one Neutral rating and one Buy rating, reflecting divergent market expectations.
Generated at21:5003/25/2026by
Aime
